Related Experiment Videos
Monoclonal antibodies and superantigens: a novel therapeutic approach
T Kalland1, M Dohlsten, P Lind
1Kabi Pharmacia Oncology, Lund, Sweden.
Abstract:
We have developed a monoclonal antibody (mAb) based therapy intended for the treatment of solid tumors utilizing both main arms of the immune system by incorporating the colon carcinoma recognizing mAb C215 and the T cell activating bacterial staphylococcal enterotoxin A (SEA) in a single hybrid molecule. The recombinant tumor specific superantigen C215-SEA retained excellent antigen binding properties while the binding to MHC class II was markedly reduced and should allow targeting of a large fraction of T cells to tumors in vivo. C215-SEA mediated T cell killing of C215 expressing tumor cells irrespective of their expression of MHC class II antigens and induced levels of IFN-gamma and TNF in mononuclear cells sufficient to completely suppress the growth of colon carcinoma cells in vitro. In initial studies of anti-tumor effects, C215Fab-SEA was found to markedly inhibit the growth of colon carcinoma cells transplanted to Scid mice adoptively transferred with human mononuclear cells.
Insights
A novel hybrid molecule, C215-SEA, combines a monoclonal antibody with a T cell activator to target solid tumors. This immunotherapy approach effectively suppresses colon carcinoma growth in vitro and in vivo.
Area of Science:
- Immunotherapy
- Oncology
- Molecular Biology
Background:
- Solid tumors present a significant challenge in cancer treatment.
- Current immunotherapies often have limitations in targeting tumor cells effectively.
- Developing novel strategies to engage both innate and adaptive immune responses is crucial.
Purpose of the Study:
- To develop a novel hybrid molecule for solid tumor treatment.
- To combine a tumor-specific monoclonal antibody (mAb) with a T cell activator.
- To assess the efficacy of this hybrid molecule in targeting and eliminating cancer cells.
Main Methods:
- Development of a recombinant hybrid molecule (C215-SEA) by fusing mAb C215 with staphylococcal enterotoxin A (SEA).
- Evaluation of antigen-binding properties and MHC class II binding affinity of C215-SEA.
- In vitro assessment of T cell-mediated tumor cell killing and cytokine production (IFN-gamma, TNF).
- In vivo studies using colon carcinoma xenografts in Scid mice with human mononuclear cell transfer.
Main Results:
- C215-SEA retained high antigen-binding affinity while exhibiting reduced MHC class II binding.
- The hybrid molecule effectively mediated T cell killing of C215-expressing tumor cells, independent of MHC class II expression.
- Significant suppression of colon carcinoma cell growth was observed in vitro due to induced cytokine levels.
- C215Fab-SEA demonstrated marked inhibition of colon carcinoma growth in vivo.
Conclusions:
- The C215-SEA hybrid molecule represents a promising new immunotherapy for solid tumors.
- This approach effectively targets T cells to tumors and enhances anti-tumor immune responses.
- Further investigation into this dual-acting immunotherapy is warranted for clinical translation.